Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddy's gets 11...

    Dr Reddy's gets 11 observations from USFDA for Hyderabad plant

    Written by supriya kashyap kashyap Published On 2017-04-29T11:57:36+05:30  |  Updated On 29 April 2017 11:57 AM IST
    Dr Reddys gets 11 observations from USFDA for Hyderabad plant

    New Delhi : Drug major Dr Reddy's Laboratories said the US health regulator has issued 11 observations after inspecting its manufacturing plant in Hyderabad.


    "The audit of our formulations manufacturing plant-3 at Bachupally, Hyderabad by the USFDA has been completed today. We have been issued a Form 483 with 11 observations," Dr Reddy's Laboratories said in a regulatory filing.


    The observations by the US Food and Drug Administration (USFDA) are mostly procedural in nature, reflecting the need to improve people capabilities and strengthen documentation and laboratory systems, it added.


    "We will address them comprehensively within the stipulated time," the drug firm said.


    Earlier this month, the USFDA issued two observations after inspecting company's manufacturing plant at Srikakulam in Andhra Pradesh.


    As per the USFDA, observations are made in Form 483 when investigators feel that conditions or practices in the facility are such that products may become adulterated or render injuries to health.


    The FDA Form 483 notifies the company's management of objectionable conditions.


    Dr Reddy's shares today ended 0.23 per cent up at Rs 2,599.15 a piece on the BSE.

    11 observationsDr Reddy'sHyderabad plantUS Food and Drug AdministrationUS health regulatorUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok